Roman Chicz, PhD, Global Project Head, Recombinant COVID Vaccine
We are moving forward with our development plan

Recombinant Adjuvanted

- Phase 2 interim results – May 2021
- Phase 3 study in progress
- Booster studies in progress

The potential of our Recombinant Adjuvanted Vaccine is being assessed:

- Broad spectrum against variants
- Good tolerability
- Boost other vaccine platforms used in the initial vaccination
- Supply-chain flexibility with an established manufacturing platform

Recently published preclinical data indicates the potential to strongly boost immune responses following primary vaccination across multiple vaccine platforms and against a broad spectrum of variants.
Our recombinant adjuvanted vaccine is in Phase 3. Pending clinical results and regulatory reviews, we are targeting submission Q4 2021.

We continue to support the global supply of primary vaccines

Leveraging our expertise and capacity to manufacture COVID-19 vaccines

- **BIONTECH**
  - 125 million doses
  - Frankfurt Site

- **Johnson&Johnson**
  - 12 million doses per month
  - Marcy/Étouile Site

- **moderna**
  - Up to 200 million doses
  - Ridgefield Site

About 500 million doses of primary vaccines will be produced by SP for the other manufacturers.
Fluzone High-Dose® vaccine and Moderna mRNA-1273 vaccine Co-administration Study Design

- Descriptive study with ~300 participants (100 per group)
- Randomized, open label, conducted in the US
- Participants received 2 doses of mRNA-1273 vaccine at least 5 months before enrollment
- mRNA-1273 vaccine (100µg) booster dose at least 5 months before enrollment
- mRNA-1273 vaccine booster dose (100µg)
- QIV-HD 2021-2022 formulation (240µg)
- Offered to Group 3 participants at D22 as part of routine medical care

Co-administration Findings Support the Recent ACIP Recommendation

The QHD00028 study results demonstrate that QIV-HD and mRNA-1273 vaccine (100µg) can be administered safely together without evidence of immunogenicity interference, supporting existing co-administration recommendations of COVID-19 and influenza vaccines.